Organizers:
Bart Vanhaesebroeck (Ludwig Institute for Cancer Research, UK)
Brian Hemmings (Friedrich Miescher Institute for Biomedical Research, Switzerland)
Melanie Welham (University of Bath, UK)
Stephen Ward (University of Bath, UK)
Timetable
|
PI3K immunology and inflammation
08:30 - 10:00 Registration
10:00 - 10:15 Welcome and Introduction
The PI3K p110delta regulates T cell differentiation and regulation
Klaus Okkenhaug (The Babraham Institute, UK)
The role of Phosphoinositide 3-kinases (PI3Ks) and Phosphoinositide dependent kinase 1 (PDK1) in T lymphocytes
Doreen Cantrell (University of Dundee, UK )
Functions of PTEN in endothelial cells and NKT cells
Akira Suzuki (Akita University, Japan)
Serendipity, inventiveness and challenges on the path to PI3Kg inhibitors
Christian Rommel (Serono International S.A., Geneva)
New approaches for the quantification of PI3K signalling
Pedro Cutillas (Ludwig Institute for Cancer Research, UK)
Role of class IA PI3K in T cell function and autoimmunity
Selected oral communication - David Fruman (University of California, USA)
PI3K and the PH domain adaptor Bam32/DAPP1 regulate B lymphocyte antigen presentation and T cell-dependant antibody responses
Selected oral communication - Aaron Marshall (University of Manitoba, Canada)
PI3-kinase isoforms and inflammatory diseases
Matthew Thomas (Novartis, UK)
14:45 - 15:15 Coffee/tea break
P110d is required for innate immunity to allografts and tumours
Selected oral communication - Aurore Saudemont (Babraham Institute, UK)
Influenza A virus NS1 protein binds p85-beta and activates PI3K/Akt signalling
Selected oral communication - Benjamin Hale (University of St Andrews, UK)
PI3K-NOS3 pathway in shock
Selected oral communication - Peter Brouckaert (University of Ghent, Belgium)
|
PI3K lipid functions and their turnover
Metabolic switching of PI3-Kinase dependent lipid signals
C. Peter Downes (University of Dundee, UK)
Analysis of the role of class I and class II PI3K catalytic isoforms in human T lymphocytes
Stephen Ward (University of Bath, UK)
18:30 - 21:00 Poster session
|
PI3K isoforms, regulation and cell biology
Physiological roles of class IA PI 3-kinase isoforms
Bart Vanhaesebroeck (Ludwig Institute for Cancer Research, UK)
In vivo effects of reduced PI3Kbeta function
Emilio Hirsch (University of Torino, Italy)
Signals in and out: PI3Kgamma in allergy and inflammation
Matthias Wymann (Centre of Biomedicine, Switzerland)
10:30 - 11:00 Coffee/tea break
Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction
John Doukas (TargeGen, USA)
Essential role of the p110delta PI 3-kinase in axonal growth and regeneration of sensory neurons
Selected oral communication - Britta Eickholt (King's College London, UK)
Signalling via PI3Ks in neutrophils
Len Stephens (The Babraham Institute, UK)
Role of Class II PI3-Kinase in cell signalling
Marco Falasca (University College London, UK)
Role of phosphoinositide phosphatase in neutrophil migration
Takehiko Sasaki (Akita University, Japan)
Gain of function mutations in p110alpha
Peter Vogt (The Scripps Research Institute, USA)
14:50 - 15:20 Coffee/tea break
|
PI3K in cell division and differentiation
Subcellular regulation allows the drosophila PI3-kinase/Akt signalling cassette to perform different functions
Selected oral communication - Clive Wilson (University of Oxford, UK)
p85-mediated control of cytokinesis, a new function for a classical regulatory subunit
Ana Carrera (National Centre of Biotechnology, Madrid, Spain)
Phosphoinositide 3-kinases and regulation of embryonic stem cell fate
Melanie Welham (University of Bath, UK)
|
PI3K downstream signalling
PLCgamma1 mediates the PI3K-dependent Akt activation in FGF-2 signalling
Selected oral communication - Tania Maffucci (University College London, UK)
17:00 - 17:15 Poster prize presentation
19:00 - 23:00 Meeting dinner incorporating Civic Reception at the Roman Baths
Wednesday 8 November 2006
Physiological functions of PKB/Akt
Brian Hemmings (Friedrich Miescher Institute for Biomedical Research, Switzerland)
Nutrient sensing in the mTOR/S6K1 signalling pathway
Pawan Gulati (University of Cincinnati, USA)
|
PI3K structural studies and inhibitors
Wednesday 8 November 2006
Structural insight into oncogenic mutants of the p110a/p85a heterodimer
Roger Williams (Medical Research Council, Cambridge, UK)
10:30 - 11:00 Coffee/tea break
Regulation of Class IA (p85/p110) and Class III (hVps34) PI3-kinases
Jonathan Backer (Albert Einstein College of Medicine, USA)
A chemical map of the PI3K family
Zachary Knight (University of California, USA)
PI3K inhibitors in 2006 ¿ 15 years of discovery after LY-294002
Selected oral communication - Thomas Rückle (Serono, Switzerland)
|
PI3K in cancer
Wednesday 8 November 2006
Drugging the PI3 kinome for cancer treatment
Paul Workman (Cancer Research UK, London)
A growth factor receptor phospho-Tyr/phopho-Ser motif that acts as a binary switch to control PI3-kinase signalling is deregulated in leukemia
Selected oral communication - Mark Guthridge (Institute of Medical and Veterinary Science, Australia)
SF1126: development of a vascular targeted pan-PI3K inhibitor for cancer therapy
Joe Garlich (Semafore Pharmaceuticals Inc., Indianapolis, USA)
Exploring the potential of PI3K inhibitors for inflammation and oncology
15:10 - 15:40 Coffee/tea break
Design and characterisation of a small molecule inhibitor specific for PTEN
Selected oral communication - Erika Rosivatz (Imperial College London, UK)
Signalling downstream of PI3-kinase
Dario Alessi (University of Dundee, UK)
16:30 - 16:40 Summary and closing remarks
|